Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2000-01-18
2004-02-03
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000, C424S464000, C424S497000, C424S451000, C424S495000
Reexamination Certificate
active
06685964
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to an orally administered pharmaceutical formulation from which an opioid, analgesic active substance is released in a controlled manner.
Many formulations of analgesic painkillers which provide controlled release of the active substance are known from the prior art.
EP-A-0647448 inter alia has already described an analgesically active preparation with delayed active substance release which consists of a plurality of substrates containing opioid in controlled release form having a diameter of 0.1 to 3 mm as a single daily dose. Substrates suitable for this purpose may assume the form of spheroids, microbeads, pellets or granules. The production of this type of substrate entails relatively elaborate formulation methods, such as for example layer accretion agglomeration processes for pellets or the extrusion/spheronisation process for spheroids.
On the other hand, many opioid active substances occur in crystalline form when they are produced, such that there is a requirement to use them directly, i.e. without the aforementioned, elaborate formulation methods during pharmaceutical production.
SUMMARY OF THE INVENTION
The object of the present invention was accordingly to provide an orally administered preparation with controlled release of at least one opioid active substance, in which the crystals obtained during production of the active substance may be used directly, i.e. without elaborate formulation steps.
This object is achieved according to the invention by the provision of an orally administered preparation with controlled release of an opioid analgesic in the form of crystals having a particle size of 10 &mgr;m to 3 mm which have at least one controlled release coating. The crystals preferably have a particle size of 50 &mgr;m to 1 mm.
The preparations according to the invention contain at least one opioid in crystalline form as the analgesic active substance. Opioids which may be used include hydromorphone, oxycodone, morphine, levorphanol, methadone, dihydrocodeine, codeine, dihydromorphine, pethidine, fentanyl, piritramide, buprenorphine, tilidine, tramadol, the particular salts thereof or mixtures thereof. Tramadol, tramadol hydrochloride, morphine, morphine hydrochloride and/or morphine sulfate are very particularly preferred as the analgesic. The active substance crystals of the preparations according to the invention may be monocrystals or have a polycrystalline structure.
Apart from the stated opioid analgesics, the preparation according to the invention may contain non-opioid analgesics which optionally exhibit a synergistic action with the opioid analgesics. These non-opioid analgesics include ibuprofen, ketoprofen, flurbiprofen, propyphenazone, paracetamol, naproxen, acematacin, acetylsalicylic acid, metamizol and the salts thereof, preferably in crystal form.
The preparations used according to the invention are distinguished by controlled, preferably delayed, release of the analgesic. This is achieved by providing the active substance crystals with at least one controlled release coating. This coating ensures that the active substance is released in a controlled, delayed manner over the desired period of time. In this manner, it is possible purposefully to control the duration of action in comparison with conventional dosage forms, i.e. those without a controlled release coating. The release of the active substance is preferably adjusted in such a manner that the preparation need be administered at most twice, preferably only once, daily.
Suitable coating materials include any pharmaceutically safe coating materials which are known to persons skilled in the art. Natural, optionally modified, or synthetic polymers are preferably used as coating materials. These are polymers, such as for example cellulose ethers or acrylic resins. Water-insoluble or water-swellable cellulose derivatives, such as alkylcellulose, preferably ethylcellulose, or water-insoluble acrylic resins, such as poly(meth)acrylic acid and/or the derivatives thereof, such as the salts, amides or esters thereof, are very particularly preferred. These materials are known from the prior art, for example Bauer, Lehmann, Osterwald, Rothgang “Überzogene Arzneiformen”, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998, pages 69 et seq., and are hereby incorporated by reference.
In addition to the water-insoluble polymers and waxes, it is optionally possible to adjust the active substance release rate by preferably also using up to 30 wt.% of non-controlled release, preferably water-soluble polymers, such as for example polyvinylpyrrolidone or water-soluble cellulose derivatives, such as hydroxyethylcellulose, hydroxypropylmethylcellulose or hydroxypropylcellulose, and/or known plasticisers.
In addition to the controlled release coating, the active substance crystals may also be provided with further coatings. Such a coating of a material other than the controlled release coating material may, for example, be applied onto the crystal surface as a non-controlled release interlayer. Coating materials preferably considered for this interlayer are cellulose ethers, polyvidones, polyacrylates or also natural polymers.
It is also possible to make the further coating, preferably over the controlled release coating, from the active substance of the crystals or from a preferably opioid analgesic differing from said active substance, from which coating this active substance is released in a non-controlled manner after oral administration. By means of this multilayer coating, it is possible to provide an initial dose for primary alleviation of the pain very rapidly after administration of the preparation, wherein the level of the analgesic may be maintained by the subsequent delayed release of the active substance. Coating materials which may be considered for this purpose are pharmaceutically safe materials in combination with the initial active substance, such as for example cellulose ethers, polyvidones or polyacrylates. It is, however, also possible to provide another pharmaceutical active substance in the non-controlled release coating in addition to or instead of the active substance of the crystals or of the further, preferably opioid, analgesic differing therefrom.
Apart from the controlled release coating, the crystals may furthermore also additionally have coatings which dissolve in a pH-dependent manner. It is thus possible, for example, to ensure that at least a proportion of the crystals of a preparation passes undissolved through the gastric tract and is not released until it reaches the intestinal tract.
In another preferred embodiment of the invention, the preparations also contain, in addition to the active substance crystals provided with a controlled release coating and optionally further coatings, which ensure controlled release of the active substance, non-controlled release active substance crystals which are, however, provided with one or more of the stated non-controlled release coatings.
Production of the opioid active substance crystals is known. The crystals are obtained directly during the necessary purification of the active substance.
The active substance crystals obtained immediately on production, preferably after recrystallisation, are provided with coatings in accordance with conventional, known processes, such as for example by spraying with solutions, dispersions and/or emulsions or by powder application processes. Coacervation is also a suitable process. To this end, an interlayer is initially applied over the individual crystals by coating the active substance crystals after the final purification step, crystallization and drying by spraying them with a lacquer solution or preferably an aqueous coating dispersion. The controlled release coating is applied thereover, again by spraying with a coating dispersion and subsequent drying. The thickness of this coating may be varied in accordance with the release profile to be achieved. Where still further coatings are applied, they are preferably produced using the
Bartholomaeus Johannes
Betzing Juergen
Crowell & Moring LLP
Gruenenthal GmbH
Page Thurman K.
Pulliam Amy E
LandOfFree
Opioid analgesics with controlled active substance release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opioid analgesics with controlled active substance release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid analgesics with controlled active substance release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3343870